Therapeutic effect of TAS-102 (A) in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy by the Kohne model (Km).

被引：1
|
作者：
Nishina, Tomohiro
Yoshino, Takayuki
Mizunuma, Nobuyuki
Yamazaki, Kentaro
Komatsu, Yoshito
Baba, Hideo
Tsuji, Akihito
Yamaguchi, Kensei
Muro, Kei
Ohtsu, Atsushi
机构：
[1] Natl Hosp Org, Shikoku Canc Ctr, Shikoku, Ehime, Japan
[2] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[3] Canc Inst Hosp, Dept Med Oncol, Tokyo, Japan
[4] Shizuoka Canc Ctr, Shizuoka, Japan
[5] Hokkaido Univ Hosp, Dept Canc Ctr, Sapporo, Hokkaido, Japan
[6] Kumamoto Univ Hosp, Kumamoto, Japan
[7] Kochi Hlth Sci Ctr, Kochi, Japan
[8] Saitama Canc Ctr, Saitama, Japan
[9] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.650
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
650
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Tas-102 for Refractory Metastatic Colorectal Cancer: A Multicenter Retrospective Cohort Study
    Conti, Matteo
    Bolzacchini, Elena
    Luchena, Giovanna
    Bertu', Lorenza
    Tagliabue, Paola
    Aglione, Stefania
    Ardizzoia, Antonio
    Arnoffi, Jessica
    Guida, Francesco Maria
    Bertolini, Alessandro
    Pastorini, Alessandro
    Duro, Maria
    Bettega, Donato
    Roda', Giovambattista
    Artale, Salvatore
    Squizzato, Alessandro
    Giordano, Monica
    CANCERS, 2023, 15 (13)
  • [22] A first combination phase I study of TAS-102 and irinotecan (hi) in Japanese patients (pts) with metastatic colorectal cancer (mCRC) refractory to fluoropyrimidine (FU) and oxaliplatin (Ox)
    Yamazaki, K.
    Doi, T.
    Yoshino, T.
    Fuse, N.
    Boku, N.
    Koizumi, W.
    Shimada, K.
    Takinishi, Y.
    Ohtsu, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S555 - S555
  • [23] Efficacy and safety of regorafenib compared to TAS-102 for refractory metastatic colorectal cancer
    Abrahao, Ana Beatriz Kinupe
    Ko, Yoo-Joung
    Chan, Kelvin K.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
    Johanna C. Bendell
    Lee S. Rosen
    Robert J. Mayer
    Jonathan W. Goldman
    Jeffrey R. Infante
    Fabio Benedetti
    Donghu Lin
    Hirokazu Mizuguchi
    Christopher Zergebel
    Manish R. Patel
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 439 - 439
  • [25] Colorectal Cancer TAS-102 effective with refractory Recurrence
    Franke, Katharina
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2015, 53 (10): : 1144 - 1144
  • [26] TAS-102 in refractory colorectal cancer: caution is needed
    Sobrero, Alberto
    LANCET ONCOLOGY, 2012, 13 (10): : 959 - 961
  • [27] Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer
    Kawahara, Hidejiro
    Mouri, Takashi
    Ishida, Kota
    Matsumoto, Nori
    Akiba, Tadashi
    Yanaga, Katsuhiko
    ANTICANCER RESEARCH, 2018, 38 (04) : 2419 - 2422
  • [28] Timing of adverse events (AEs) in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients (pts) with metastatic colorectal cancer (mCRC)
    Shinozaki, E.
    Laurent, S.
    Gravalos, C.
    Benavides, M.
    Longo Munoz, F.
    Mizuguchi, H.
    Wahba, M.
    Ychou, M.
    Ciardiello, F.
    Siena, S.
    Yamaguchi, K.
    Muro, K.
    Denda, T.
    Tsuji, Y.
    Loehrer, P.
    Lenz, H. J.
    Tebbutt, N.
    Mayer, R. J.
    Van Cutsem, E.
    Ohtsu, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S383 - S384
  • [29] Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer
    Kawahara, Hidejiro
    Yanaga, Katsuhiko
    CANCER SCIENCE, 2018, 109 : 601 - 601
  • [30] Low rates of hospitalizations with TAS-102 in the European (EU) subregion of the Phase 3 RECOURSE trial in patients (pts) with metastatic colorectal cancer (mCRC)
    Falcone, A.
    Garcia-Carbonero, R.
    Tabernero, J.
    Sobrero, A.
    Peeters, M.
    Zaniboni, A.
    Hochster, H.
    Lenz, H. J.
    Tran, B.
    Yamaguchi, K.
    Muro, K.
    Denda, T.
    Tsuji, Y.
    Wahba, M.
    Benedetti, F.
    Ohtsu, A.
    Mayer, R. J.
    Van Cutsem, E.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S383 - S383
12345